Immunic Inc (IMUX) Financial

Immunic, Inc. is a clinical-stage biopharmaceutical company that develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York, and currently employs 91 full-time employees. It went public on April 17, 2014. The firm is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. Its lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has demonstrated therapeutic activity in phase II clinical trials in patients with relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is designed to restore intestinal barrier function and regenerate bowel epithelium, potentially offering applicability across various gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing and represents a next-generation molecule being developed to specifically address the needs of gastrointestinal diseases.